Open Access Open Access  Restricted Access Subscription or Fee Access

Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access

Elizabeth Kolb, MS, Mark Rueth, PharmD

Abstract


Introduction: Pharmacy-level challenges that exist for patients when seeking to fill buprenorphine prescriptions at traditional retail pharmacies can result in a less than optimal treatment experience. High patient satisfaction with treatment for opioid use disorder (OUD), which for oral buprenorphine treatment includes the necessary step of obtaining medication after being prescribed, is associated with positive health outcomes and, therefore, is of great clinical interest. The objective of this study was to examine patient satisfaction when participating in a pharmacy program that coordinated buprenorphine delivery and provision to patients at office visits instead of requiring patients to fill their prescriptions at local pharmacies.

Methods: We conducted a voluntary and anonymous survey to assess patient satisfaction when the need to seek a retail pharmacy to fill buprenorphine prescriptions was alleviated. The survey was completed by 714 patients prescribed buprenorphine for OUD treated at 15 office-based opioid treatment clinics that integrated the clinic-based pharmacy program as an extension of their treatment services. The survey consisted of 16 questions evaluating satisfaction with the pharmacy program and prior retail pharmacy experience.

Results: Majority of patient respondents reported high levels of satisfaction with the pharmacy program. Specifically, 97.6 percent (n = 697) of respondents noted feeling respected and/or that the pharmacy staff cares about their wellbeing, 91.7 percent (n = 655) of respondents reported that they are more likely to make their treatment appointments and/or stick to their treatment plan when the physical need to seek a pharmacy to fill their prescription was alleviated. The survey resulted in an 83.8 Net Promoter Score, further supporting a high patient satisfaction. Patient responses regarding how the program impacted their recovery illustrated common themes of more convenient, more private, judgment free, quicker, and stress free. The survey responses also validated previously reported pharmacy-level barriers for patients with OUD that the program sought to alleviate. Transportation challenges and/or undue time spent obtaining medication were indicated by 77.6 percent (n = 528) of respondents, 56.8 percent (n = 386) of respondents experienced feelings of stigma or shame at retail pharmacies was experienced by 56.8% (n = 386) of respondents, and pharmacies not reliably stocking their medication was indicated by 37.1 percent (n = 252) of respondents.

Conclusions: The survey findings demonstrate that patients were highly satisfied with the provision of pharmacy-dispensed buprenorphine at their treatment visit in place of having to seek to fill prescriptions at retail pharmacies. Responses indicated the pharmacy program may also be a motivating factor for patients to attend treatment appointments. Continuing to develop and research strategies that alleviate physical barriers to buprenorphine access and result in high patient satisfaction, like this clinic-based pharmacy program studied, have meaningful implications for both patients and treatment providers.


Keywords


patient satisfaction, pharmacy experience, buprenorphine, medication access, opioid use disorder

Full Text:

PDF

References


Wright W, Gorman J, Odorzynski M, et al.: Integrated pharmacies at community mental health centers: Medication adherence and outcomes. J Manag Care Spec Pharm. 2016; 22(11): 1330-1336.

Khan A, Khan Q, Kolb E: Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes. J Subst Abuse Treat. 2021; 123: 108256.

Barbosa CD, Balp M-M, Kulich K, et al.: A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012; 6: 39-48.

Kelly S, O’Grady K, Brown B, et al.: The role of patient satisfaction in methadone treatment. Am J Drug Alcohol Abuse. 2010; 36: 150-154.

Cooper H, Cloud D, Freeman P, et al.: Buprenorphine dispensing in an epicenter of the US opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020; 85: 102701.

Samina S, Gerber B, Sharp L: Traveling towards disease: Transportation barriers to health care access. J Community Health. 2014; 38(5): 976-996.

Cooper H, Cloud D, Young A, et al.: When prescribing isn’t enough—Pharmacy-level barriers to buprenorphine access. N Engl J Med. 2020; 383: 703-705.

Haelle T: Pharmacist stigma a barrier to rural buprenorphine access. Clin Psychiatr News. 2019. Available at https://www.mdedge.com/psychiatry/article/205251/addiction-medicine/pharmacist-stigma-barrier-rural-buprenorphine-access. Accessed September 1, 2020.

Merrill JO: Policy progress for physician treatment of opiate addiction. J Gen Intern Med. 2002; 17(5): 361-368.

Drug Store News: Rx impact: A drug store news special report. 2016. Available at https://drugstorenews.com/pharmacy/numbers-how-community-pharmacists-measure. Accessed September 15, 2020.

Gourley G, Gourley D, La Monica Rigolosi E, et al.: Development and validation of the pharmaceutical care satisfaction questionnaire. Am J Manag Care. 2001; 7(5): 461-466.

Malewski D, Ream A, Gaither C: Patient satisfaction with community pharmacy: Comparing urban and suburban chain-pharmacy populations. Res Soc Adm Pharm. 2015; 11(1): 121-128.

Flanagan P, Kainth S, Nissen L: Satisfaction survey for a medication management program: Satisfaction guaranteed? Can J Hosp Pharm. 2013; 66(6): 355-360.

Keiningham T, Aksoy L, Cooil B, et al.: A holistic examination of net promoter. J Database Mark Cust Strategy Manag. 2008; 15(2): 79-90.

National Association of Specialty Pharmacy: Actionable insights from the 2016/2017 national association of specialty pharmacy patient survey program. 2017. Available at http://naspnet.org/wp-content/uploads/2017/09/NASP-Patient-Survey-White-Paper-Final-091817.pdf. Accessed September 19, 2020.

Bozinoff N, Anderson B, Bailey G, et al.: Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med. 2018; 12(1): 19-23.

Kennedy-Hendricks A, Barry C, Gollust S, et al.: Social stigma towards persons with prescription opioid use disorder: Associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017; 68(5): 462-469.

Volkow ND, Frieden TR, Hyde PS, et al.: Medication-assisted therapies—Tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370(22): 2063-2066.

Blendon RJ, Benson JM: The public and the opioid-abuse epidemic. N Engl J Med. 2018; 378(5): 407-411.

Dubey M, Ghosh R, Chatterjee S, et al.: COVID-19 and addiction. Diabetes Metab Syndr. 2020; 14(5): 817-823.




DOI: https://doi.org/10.5055/jom.2021.0645

Refbacks

  • There are currently no refbacks.